On Monday, Viracta Therapeutics Inc (NASDAQ: VIRX) opened lower -4.62% from the last session, before settling in for the closing price of $0.22. Price fluctuations for VIRX have ranged from $0.13 to $1.31 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -25.00%. Company’s average yearly earnings per share was noted 35.23% at the time writing. With a float of $28.01 million, this company’s outstanding shares have now reached $39.74 million.
Considering the fact that the conglomerate employs 40 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 55.42%, operating margin of -6397.02%, and the pretax margin is -5865.72%.
Viracta Therapeutics Inc (VIRX) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Viracta Therapeutics Inc is 29.53%, while institutional ownership is 13.00%. The most recent insider transaction that took place on Feb 27 ’24, was worth 2,493. In this transaction CFO and COO of this company sold 3,405 shares at a rate of $0.73, taking the stock ownership to the 102,306 shares.
Viracta Therapeutics Inc (VIRX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 35.23% per share during the next fiscal year.
Viracta Therapeutics Inc (NASDAQ: VIRX) Trading Performance Indicators
Check out the current performance indicators for Viracta Therapeutics Inc (VIRX). In the past quarter, the stock posted a quick ratio of 0.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.10, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.56 in one year’s time.
Technical Analysis of Viracta Therapeutics Inc (VIRX)
Compared to the last year’s volume of 5.35 million, its volume of 4.01 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 52.61%. Additionally, its Average True Range was 0.03.
During the past 100 days, Viracta Therapeutics Inc’s (VIRX) raw stochastic average was set at 18.95%, which indicates a significant decrease from 59.87% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 208.40% in the past 14 days, which was higher than the 114.07% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.1859, while its 200-day Moving Average is $0.4633. Nevertheless, the first resistance level for the watch stands at $0.2389 in the near term. At $0.2650, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.2912. If the price goes on to break the first support level at $0.1866, it is likely to go to the next support level at $0.1604. Should the price break the second support level, the third support level stands at $0.1343.
Viracta Therapeutics Inc (NASDAQ: VIRX) Key Stats
There are currently 39,744K shares outstanding in the company with a market cap of 8.45 million. Presently, the company’s annual sales total 0 K according to its annual income of -51,060 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -10,550 K.
